Genomic Testing and Resulting Medical Decisions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-30

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is no evidence available about which molecular profiling methods are currently used for cancer patients in Austrian clinical practice. The construction of the registry proposed as a completely independent research endeavor, will be helpful for scientific evaluation and the establishment of highly credible data.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer

NCT05032092

Locally Advanced Carcinoma Metastatic Cancer

ACTIVE_NOT_RECRUITING NA

Mutational Oncology in Clinical Practice

NCT06020625

Genome Instability Genetic Predisposition to Disease Gene Rearrangement

RECRUITING NA

Establishment of a Tumor Bank for Blood Samples

NCT01763125

Ovarian Neoplasms Breast Neoplasms Colorectal Neoplasms +3 more

RECRUITING

Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples

NCT01703585

Colorectal Cancer Breast Cancer Gynecological Cancer +3 more

COMPLETED

Utilization of Genomic Information to Augment Chemotherapy Decision-making for People With Incurable Malignancies

NCT01802905

Advanced Incurable Cancers

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the situation of enormous possible beneficial options for patients, health care systems, researchers and companies and the simultaneously present high number of uncertainties, the establishment of an independent registry for patients undergoing any type of comprehensive genomic profiling offers many advantages.

In particular, an overview of the speed of development, the "market penetration", the use of the technology in specific indications (tumor types, stages and in specific situations of unresponsiveness to certain drugs), the frequency by which treatment decisions will definitely follow the result of comprehensive genomic profiling and the reasons for this, the treatment outcome of such patients, the platform technologies applied (in-house (which types), vs. commercial) and the development of these parameters over time and in relation to the development of novel drugs will be analyzed.

The registry proposes to cover the time period from the years 2016 to 2019, which will allow for assessment of both the current and emerging landscape of genomic/molecular testing practice in Austria and effect of molecular profiling on patient care and outcome.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer of Unknown Origin Cancer Refractory Cancer of Stomach Cancer Head Neck Cancer of Skin Cancer, Lung Cancer Colorectal Cancer of Esophagus Cancer, Bladder Cancer, Uterus Cancer Cervix Cancer Liver Cancer, Kidney Cancer, Breast Hematologic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genomic testing

Genomic profiling, indicated as assessed by the medical need and as deemed appropriate by the physician according to routine practice

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

This registry will include cancer patients for which broad genomic profiling is indicated as assessed by the medical need and as deemed appropriate by the physician, for example

* cancer with high mutational load and suspicion of regular or frequent formation of neoantigens

* skin, lung, stomach, esophagus, colorectum, bladder, uterus, cervix, liver, head and neck, kidney, breast
* lymphoma B-cell
* any other neoplastic disease where molecular targeting is performed but treatment fails
* cancer of unknown primary origin (CUP)
* planned or already carried out comprehensive genomic testing as of Jan 1, 2016 note: this registry will not initially register patients who are tested for only 1-5 mutations by conventional means, but patients undergoing genomic profiling based on NGS)
* a patient´s signed informed consent
* Patients ≥ 18 years of age

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No